Q BioMed Inc (OTCQB:QBIO) CEO Denis Corin tells Proactive the privately held global disruption aggregator Aedesius Holdings Ltd, run by Geoffrey Fatzinger, Q BioMed's global head of regulatory affairs, has committed to investing up to $30 million in the company via a securities agreement. Corin says its the largest single investment so far for the biotech, allowing the group to move forward with its commercial roll-out plans for its cancer bone pain drug Strontium89, as well as advance its development opportunities.
Q BioMed Inc 'thrilled' with $30M insider investment to help advance its pipeline of therapeutics
